Annexin A5 and the failing heart; lost or found in translation?

European Heart Journal

Volumn 28, Issue 22, 2007, Pages 2695-2696

  Hofstra, Leonard ^a   Heymans, Stephane ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOCORTIN 5;

APOPTOSIS; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; EDITORIAL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC DYSFUNCTION; UPREGULATION;

AGED; ANIMALS; ANNEXIN A5; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; UP-REGULATION;

EID: 36249012121     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehm452     Document Type: Editorial

References (12)

1. Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. Am J Cardiol 2006;97:13F-25F.
2. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; in press.
3. Wu AH. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 2006;152:828-834.
4. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-1224.
5. Ravassa S, González A, López B, Beaumont J, Querejeta R, Larman M, Díez J. Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction. Eur Heart J 2007;28:2785-2791. First Published on August 31, 2007, doi:10.1093/eurheartj/ehm370.
6. Camors E, Monceau V, Charlemagne D. Annexins and Ca2+ handling in the heart. Cardiovasc Res 2005;65:793-802.
7. Gaipl US, Munoz LE, Rodel F, Pausch F, Frey B, Brachvogel B, von der Mark K, Poschl E. Modulation of the immune system by dying cells and the phosphatidylserine-ligand annexin A5. Autoimmunity 2007;40:254- 259.
8. Cederholm A, Frostegard J. Annexin A5 in cardiovascular disease and systemic lupus erythematosus. Immunobiology 2005;210:761-768.
9. Boersma HH, Kietselaer BL, Stolk LM, Bennaghmouch A, Hofstra L, Narula J, Heidendal GA, Reutelingsperger CP. Past, present, and future of annexin A5: from protein discovery to clinical applications. J Nucl Med 2005;46:2035-2050.
10. Kietselaer BL, Reutelingsperger CP, Boersma HH, Heidendal GA, Liem IH, Crijns HJ, Narula J, Hofstra L. Noninvasive detection of programmed cell loss with 99mTc-labeled annexin A5 in heart failure. J Nucl Med 2007;48: 562-567.
11. Dumont EA, Hofstra L, van Heerde WL, van den Eijnde S, Doevendans PA, DeMuinck E, Daemen MA, Smits JF, Frederik P, Wellens HJ, Daemen MJ, Reutelingsperger CP. Cardiomyocyte death induced by myocardial ischemia and reperfusion: measurement with recombinant human annexin-V in a mouse model. Circulation 2000;102:1564-1568.
12. Brachvogel B, Dikschas J, Moch H, Welzel H, von der Mark K, Hofmann C, Poschl E. Annexin A5 is not essential for skeletal development. Mol Cell Biol 2003;23:2907-2913.